Two specific drugs, BMS-345541 and purvalanol A induce apoptosis of HTLV-1 infected cells through inhibition of the NF-kappaB and cell cycle pathways

AIDS Research and Therapy

Volumn 5, Issue , 2008, Pages

  Agbottah, Emmanuel ^a   Yeh, Wen I ^a   Berro, Reem ^a   Klase, Zachary ^a   Pedati, Caitlin ^a   Kehn Hall, Kyleen ^a   Wu, Weilin ^a   Kashanchi, Fatah ^a,b,c  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c J CRAIG VENTER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 DIAMINOPURINE; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 3 (4 TERT BUTYLPHENYLSULFONYL) 2 PROPENENITRILE; 4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; 6 N,N DIMETHYLADENINE; ALOISINE A; ALSTERPAULLONE; ANTIVIRUS AGENT; BOHEMINE; CASPASE 3; CGP 74514A; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; DIETHYLMALEATE; FLAVONE; FLAVOPIRIDOL; GAG PROTEIN; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDIRUBIN 3' MONOXIME 5' IODO; KENPAULLONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; OLOMOUCINE; PARTHENOLIDE; PURVALANOL A; ROSCOVITINE; SC 514; UNINDEXED DRUG; WEDELOLACTONE; WHI P 180;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE; CELL SURVIVAL; CONCENTRATION RESPONSE; DRUG SCREENING; ENZYME ASSAY; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1 INFECTION; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TARGETING; T LYMPHOCYTE;

EID: 48449105366     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-5-12     Document Type: Article

References (87)

1. Verdonck K Gonzalez E Van Dooren S Vandamme AM Vanham G Gotuzzo E Human T-lymphotropic virus 1: Recent knowledge about an ancient infection Lancet Infect Dis 2007, 7:266-281. 10.1016/S1473-3099(07)70081-6 17376384
2. Matsuoka M Jeang KT Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation Nat Rev Cancer 2007, 7:270-280. 10.1038/nrc2111 17384582
3. Peloponese JM Jr. Kinjo T Jeang KT Human T-cell leukemia virus type 1 Tax and cellular transformation Int J Hematol 2007, 86:101-106. 10.1532/ IJH97.07087 17875521
4. Suzuki T Hirai H Yoshida M Tax protein of HTLV-1 interacts with the Rel homology domain of NF-kappa B p65 and c-Rel proteins bound to the NF-kappa B binding site and activates transcription Oncogene 1994, 9:3099-3105. 7936632
5. Yin MJ Christerson LB Yamamoto Y Kwak YT Xu S Mercurio F Barbosa M Cobb MH Gaynor RB HTLV-I Tax protein binds to MEKK1 to stimulate IkappaB kinase activity and NF-kappaB activation Cell 1998, 93:875-884. 10.1016/ S0092-8674(00)81447-6 9630230
6. Xiao G Cvijic ME Fong A Harhaj EW Uhlik MT Waterfield M Sun SC Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: Evidence for the involvement of IKKalpha Embo J 2001, 20:6805-6815. 125766 11726516 10.1093/emboj/20.23.6805
7. Caron C Rousset R Beraud C Moncollin V Egly JM Jalinot P Functional and biochemical interaction of the HTLV-I Tax1 transactivator with TBP Embo J 1993, 12:4269-4278. 413723 8223437
8. Clemens KE Piras G Radonovich MF Choi KS Duvall JF DeJong J Roeder R Brady JN Interaction of the human T-cell lymphotropic virus type 1 tax transactivator with transcription factor IIA Mol Cell Biol 1996, 16:4656-4664. 231465 8756622
9. Colgin MA Nyborg JK The human T-cell leukemia virus type 1 oncoprotein Tax inhibits the transcriptional activity of c-Myb through competition for the CREB binding protein J Virol 1998, 72:9396-9399. 110368 9765496
10. Gachon F Thebault S Peleraux A Devaux C Mesnard JM Molecular interactions involved in the transactivation of the human T-cell leukemia virus type 1 promoter mediated by Tax and CREB-2 (ATF-4) Mol Cell Biol 2000, 20:3470-3481. 85640 10779337 10.1128/ MCB.20.10.3470-3481.2000
11. Harrod R Tang Y Nicot C Lu HS Vassilev A Nakatani Y Giam CZ An exposed KID-like domain in human T-cell lymphotropic virus type 1 Tax is responsible for the recruitment of coactivators CBP/p300 Mol Cell Biol 1998, 18:5052-5061. 109090 9710589
12. Nicot C Mahieux R Opavsky R Cereseto A Wolff L Brady JN Franchini G HTLV-I Tax transrepresses the human c-Myb promoter independently of its interaction with CBP or p300 Oncogene 2000, 19:2155-2164. 10.1038/ sj.onc.1203536 10815807
13. Yin MJ Paulssen EJ Seeler JS Gaynor RB Protein domains involved in both in vivo and in vitro interactions between human T-cell leukemia virus type I tax and CREB J Virol 1995, 69:3420-3432. 189054 7745688
14. Kashanchi F Brady JN Transcriptional and post-transcriptional gene regulation of HTLV-1 Oncogene 2005, 24:5938-5951. 10.1038/sj.onc.1208973 16155601
15. Aggarwal BB Nuclear factor-kappaB: The enemy within Cancer Cell 2004, 6:203-208. 10.1016/j.ccr.2004.09.003 15380510
16. Okamoto T Sakurada S Yang JP Merin JP Regulation of NF-kappa B and disease control: Identification of a novel serine kinase and thioredoxin as effectors for signal transduction pathway for NF-kappa B activation Curr Top Cell Regul 1997, 35:149-161. 9192179
17. Basseres DS Baldwin AS Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression Oncogene 2006, 25:6817-6830. 10.1038/sj.onc.1209942 17072330
18. Taylor GP Matsuoka M Natural history of adult T-cell leukemia/lymphoma and approaches to therapy Oncogene 2005, 24:6047-6057. 10.1038/ sj.onc.1208979 16155611
19. Ghosh S Karin M Missing pieces in the NF-kappaB puzzle Cell 2002, 109(Suppl):S81-96. 10.1016/S0092-8674(02)00703-1 11983155
20. Pikarsky E Porat RM Stein I Abramovitch R Amit S Kasem S Gutkovich-Pyest E Urieli-Shoval S Galun E Ben-Neriah Y NF-kappaB functions as a tumour promoter in inflammation-associated cancer Nature 2004, 431:461-466. 10.1038/nature02924 15329734
21. Gilmore TD Introduction to NF-kappaB: Players, pathways, perspectives Oncogene 2006, 25:6680-6684. 10.1038/sj.onc.1209954 17072321
22. Karin M Cao Y Greten FR Li ZW NF-kappaB in cancer: From innocent bystander to major culprit Nat Rev Cancer 2002, 2:301-310. 10.1038/ nrc780 12001991
23. Schesser K Spiik AK Dukuzumuremyi JM Neurath MF Pettersson S Wolf-Watz H The yopJ locus is required for Yersinia-mediated inhibition of NF-kappaB activation and cytokine expression: YopJ contains a eukaryotic SH2-like domain that is essential for its repressive activity Mol Microbiol 1998, 28:1067-1079. 10.1046/j.1365-2958.1998.00851.x 9680199
24. Pomerantz JL Baltimore D Two pathways to NF-kappaB Mol Cell 2002, 10:693-695. 10.1016/S1097-2765(02)00697-4 12419209
25. Mori N Yamada Y Ikeda S Yamasaki Y Tsukasaki K Tanaka Y Tomonaga M Yamamoto N Fujii M Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells Blood 2002, 100:1828-1834. 10.1182/ blood-2002-01-0151 12176906
26. Mori N Fujii M Iwai K Ikeda S Yamasaki Y Hata T Yamada Y Tanaka Y Tomonaga M Yamamoto N Constitutive activation of transcription factor AP-1 in primary adult T-cell leukemia cells Blood 2000, 95:3915-3921. 10845928
27. Bonizzi G Bebien M Otero DC Johnson-Vroom KE Cao Y Vu D Jegga AG Aronow BJ Ghosh G Rickert RC Karin M Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers Embo J 2004, 23:4202-4210. 524385 15470505 10.1038/ sj.emboj.7600391
28. Derudder E Dejardin E Pritchard LL Green DR Korner M Baud V RelB/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotoxin-beta receptor activation: Critical roles for p100 J Biol Chem 2003, 278:23278-23284. 10.1074/jbc.M300106200 12709443
29. Yilmaz ZB Weih DS Sivakumar V Weih F RelB is required for Peyer's patch development: Differential regulation of p52-RelB by lymphotoxin and TNF Embo J 2003, 22:121-130. 140043 12505990 10.1093/emboj/cdg004
30. Schwabe RF Schnabl B Kweon YO Brenner DA CD40 activates NF-kappa B and c-Jun N-terminal kinase and enhances chemokine secretion on activated human hepatic stellate cells J Immunol 2001, 166:6812-6819. 11359840
31. Hironaka N Mochida K Mori N Maeda M Yamamoto N Yamaoka S Tax-independent constitutive IkappaB kinase activation in adult T-cell leukemia cells Neoplasia 2004, 6:266-278. 1502096 15153339 10.1593/neo.03388
32. Chu ZL Shin YA Yang JM DiDonato JA Ballard DW IKKgamma mediates the interaction of cellular IkappaB kinases with the tax transforming protein of human T cell leukemia virus type 1 J Biol Chem 1999, 274:15297-15300. 10.1074/jbc.274.22.15297 10336413
33. Harhaj EW Sun SC IKKgamma serves as a docking subunit of the IkappaB kinase (IKK) and mediates interaction of IKK with the human T-cell leukemia virus Tax protein J Biol Chem 1999, 274:22911-22914. 10.1074/ jbc.274.33.22911 10438454
34. Jin DY Giordano V Kibler KV Nakano H Jeang KT Role of adapter function in oncoprotein-mediated activation of NF-kappaB. Human T-cell leukemia virus type I Tax interacts directly with IkappaB kinase gamma J Biol Chem 1999, 274:17402-17405. 10.1074/jbc.274.25.17402 10364167
35. Yamaoka S Courtois G Bessia C Whiteside ST Weil R Agou F Kirk HE Kay RJ Israel A Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation Cell 1998, 93:1231-1240. 10.1016/S0092-8674(00)81466-X 9657155
36. Karunagaran D. ABB Transcription factors as targets fr the drug development Molecular pathomechanisms and new trends in drug development New York, NY, Harwood Academic Publisher Keri G. TI 2002:76-91.
37. Mori N Fujii M Ikeda S Yamada Y Tomonaga M Ballard DW Yamamoto N Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells Blood 1999, 93:2360-2368. 10090947
38. Nicot C Mahieux R Takemoto S Franchini G Bcl-X(L) is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples Blood 2000, 96:275-281. 10891462
39. Dewan MZ Terashima K Taruishi M Hasegawa H Ito M Tanaka Y Mori N Sata T Koyanagi Y Maeda M Kubuki Y Okayama A Fujii M Yamamoto N Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/gammac(null) mice: Suppression by an inhibitor against NF-kappaB J Virol 2003, 77:5286-5294. 153944 12692230 10.1128/ JVI.77.9.5286-5294.2003
40. Ohsugi T Horie R Kumasaka T Ishida A Ishida T Yamaguchi K Watanabe T Umezawa K Urano T In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia Carcinogenesis 2005, 26:1382-1388. 10.1093/carcin/bgi095 15831528
41. Watanabe M Ohsugi T Shoda M Ishida T Aizawa S Maruyama-Nagai M Utsunomiya A Koga S Yamada Y Kamihira S Okayama A Kikuchi H Uozumi K Yamaguchi K Higashihara M Umezawa K Watanabe T Horie R Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia Blood 2005, 106:2462-2471. 10.1182/ blood-2004-09-3646 15956280
42. Ohsugi T Kumasaka T Ishida A Ishida T Horie R Watanabe T Umezawa K Yamaguchi K In vitro and in vivo antitumor activity of the NF-kappaB inhibitor DHMEQ in the human T-cell leukemia virus type I-infected cell line, HUT-102 Leuk Res 2006, 30:90-97. 10.1016/j.leukres.2005.06.001 16002138
43. El-Sabban ME Nasr R Dbaibo G Hermine O Abboushi N Quignon F Ameisen JC Bex F de The H Bazarbachi A Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation Blood 2000, 96:2849-2855. 11023521
44. Nasr R Rosenwald A El-Sabban ME Arnulf B Zalloua P Lepelletier Y Bex F Hermine O Staudt L de The H Bazarbachi A Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells Blood 2003, 101:4576-4582. 10.1182/ blood-2002-09-2986 12560223
45. Satou Y Nosaka K Koya Y Yasunaga JI Toyokuni S Matsuoka M Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro Leukemia 2004, 18:1357-1363. 10.1038/sj.leu.2403400 15190257
46. Lemoine FJ Marriott SJ Accelerated G(1) phase progression induced by the human T cell leukemia virus type I (HTLV-I) Tax oncoprotein J Biol Chem 2001, 276:31851-31857. 10.1074/jbc.M105195200 11435441
47. Suzuki T Kitao S Matsushime H Yoshida M HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p16INK4A and counteracts its inhibitory activity towards CDK4 Embo J 1996, 15:1607-1614. 450070 8612584
48. Parker SF Perkins ND Gitlin SD Nabel GJ A cooperative interaction of human T-cell leukemia virus type 1 Tax with the p21 cyclin-dependent kinase inhibitor activates the human immunodeficiency virus type 1 enhancer J Virol 1996, 70:5731-5734. 190543 8764097
49. Low KG Dorner LF Fernando DB Grossman J Jeang KT Comb MJ Human T-cell leukemia virus type 1 Tax releases cell cycle arrest induced by p16INK4a J Virol 1997, 71:1956-1962. 191279 9032327
50. Jeang KT Giam CZ Majone F Aboud M Life, death, and tax: Role of HTLV-I oncoprotein in genetic instability and cellular transformation J Biol Chem 2004, 279:31991-31994. 10.1074/jbc.R400009200 15090550
51. Marriott SJ Semmes OJ Impact of HTLV-I Tax on cell cycle progression and the cellular DNA damage repair response Oncogene 2005, 24:5986-5995. 10.1038/sj.onc.1208976 16155605
52. de La Fuente C Santiago F Chong SY Deng L Mayhood T Fu P Stein D Denny T Coffman F Azimi N Mahieux R Kashanchi F Overexpression of p21(waf1) in human T-cell lymphotropic virus type 1-infected cells and its association with cyclin A/cdk2 J Virol 2000, 74:7270-7283. 112248 10906181 10.1128/JVI.74.16.7270-7283.2000
53. Cereseto A Diella F Mulloy JC Cara A Michieli P Grassmann R Franchini G Klotman ME p53 functional impairment and high p21waf1/cip1 expression in human T-cell lymphotropic/leukemia virus type I-transformed T cells Blood 1996, 88:1551-1560. 8781409
54. Pise-Masison CA Radonovich M Sakaguchi K Appella E Brady JN Phosphorylation of p53: A novel pathway for p53 inactivation in human T-cell lymphotropic virus type 1-transformed cells J Virol 1998, 72:6348-6355. 109779 9658074
55. Pise-Masison CA Mahieux R Jiang H Ashcroft M Radonovich M Duvall J Guillerm C Brady JN Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-kappaB pathway and is dependent on p53 phosphorylation Mol Cell Biol 2000, 20:3377-3386. 85630 10779327 10.1128/MCB.20.10.3377-3386.2000
56. Neuveut C Low KG Maldarelli F Schmitt I Majone F Grassmann R Jeang KT Human T-cell leukemia virus type 1 Tax and cell cycle progression: Role of cyclin D-cdk and p110Rb Mol Cell Biol 1998, 18:3620-3632. 108944 9584203
57. Akagi T Ono H Shimotohno K Expression of cell-cycle regulatory genes in HTLV-I infected T-cell lines: Possible involvement of Tax1 in the altered expression of cyclin D2, p18Ink4 and p21Waf1/Cip1/Sdi1 Oncogene 1996, 12:1645-1652. 8622884
58. de La Fuente C Deng L Santiago F Arce L Wang L Kashanchi F Gene expression array of HTLV type 1-infected T cells: Up-regulation of transcription factors and cell cycle genes AIDS Res Hum Retroviruses 2000, 16:1695-1700. 10.1089/08892220050193164 11080812
59. Huang Y Ohtani K Iwanaga R Matsumura Y Nakamura M Direct trans-activation of the human cyclin D2 gene by the oncogene product Tax of human T-cell leukemia virus type I Oncogene 2001, 20:1094-1102. 10.1038/sj.onc.1204198 11314046
60. Santiago F Clark E Chong S Molina C Mozafari F Mahieux R Fujii M Azimi N Kashanchi F Transcriptional up-regulation of the cyclin D2 gene and acquisition of new cyclin-dependent kinase partners in human T-cell leukemia virus type 1-infected cells J Virol 1999, 73:9917-9927. 113041 10559304
61. Iwanaga R Ohtani K Hayashi T Nakamura M Molecular mechanism of cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I Oncogene 2001, 20:2055-2067. 10.1038/ sj.onc.1204304 11360190
62. Kehn K Deng L de la Fuente C Strouss K Wu K Maddukuri A Baylor S Rufner R Pumfery A Bottazzi ME Kashanchi F The role of cyclin D2 and p21/waf1 in human T-cell leukemia virus type 1 infected cells Retrovirology 2004, 1:6. 420262 15169570 10.1186/1742-4690-1-6
63. Chlichlia K Moldenhauer G Daniel PT Busslinger M Gazzolo L Schirrmacher V Khazaie K Immediate effects of reversible HTLV-1 tax function: T-cell activation and apoptosis Oncogene 1995, 10:269-277. 7838527
64. Burke JR Pattoli MA Gregor KR Brassil PJ MacMaster JF McIntyre KW Yang X Iotzova VS Clarke W Strnad J Qiu Y Zusi FC BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice J Biol Chem 2003, 278:1450-1456. 10.1074/jbc.M209677200 12403772
65. Yang J Amiri KI Burke JR Schmid JA Richmond A BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways Clin Cancer Res 2006, 12:950-960. 10.1158/1078-0432.CCR-05-1220 16467110
66. Petropoulos CJ Givol I Hughes SH Comparative analysis of the structure and function of the chicken c-myc and v-myc genes: V-myc is a more potent inducer of cell proliferation and apoptosis than c-myc Oncogene 1996, 12:2611-2621. 8700520
67. Mauxion F Jamieson C Yoshida M Arai K Sen R Comparison of constitutive and inducible transcriptional enhancement mediated by kappa B-related sequences: Modulation of activity in B cells by human T-cell leukemia virus type I tax gene Proc Natl Acad Sci U S A 1991, 88:2141-2145. 51185 2006151 10.1073/pnas.88.6.2141
68. Arima N Molitor JA Smith MR Kim JH Daitoku Y Greene WC Human T-cell leukemia virus type I Tax induces expression of the Rel-related family of kappa B enhancer-binding proteins: Evidence for a pretranslational component of regulation J Virol 1991, 65:6892-6899. 250789 1719236
69. Nicholson DW Ali A Thornberry NA Vaillancourt JP Ding CK Gallant M Gareau Y Griffin PR Labelle M Lazebnik YA Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis Nature 1995, 376:37-43. 10.1038/376037a0 7596430
70. Han Z Hendrickson EA Bremner TA Wyche JH A sequential two-step mechanism for the production of the mature p17:p12 form of caspase-3 in vitro J Biol Chem 1997, 272:13432-13436. 10.1074/jbc.272.20.13432 9148968
71. Rice WG Hillyer CD Harten B Schaeffer CA Dorminy M Lackey DA 3rd Kirsten E Mendeleyev J Buki KG Hakam A Induction of endonuclease-mediated apoptosis in tumor cells by C-nitroso-substituted ligands of poly(ADP-ribose) polymerase Proc Natl Acad Sci U S A 1992, 89:7703-7707. 49779 1502187 10.1073/pnas.89.16.7703
72. Lazebnik YA Kaufmann SH Desnoyers S Poirier GG Earnshaw WC Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE Nature 1994, 371:346-347. 10.1038/371346a0 8090205
73. Kaufmann SH Desnoyers S Ottaviano Y Davidson NE Poirier GG Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis Cancer Res 1993, 53:3976-3985. 8358726
74. Sherr CJ Roberts JM CDK inhibitors: Positive and negative regulators of G1-phase progression Genes Dev 1999, 13:1501-1512. 10.1101/ gad.13.12.1501 10385618
75. Villerbu N Gaben AM Redeuilh G Mester J Cellular effects of purvalanol A: A specific inhibitor of cyclin-dependent kinase activities Int J Cancer 2002, 97:761-769. 10.1002/ijc.10125 11857351
76. Bain J McLauchlan H Elliott M Cohen P The specificities of protein kinase inhibitors: An update Biochem J 2003, 371:199-204. 1223271 12534346 10.1042/BJ20021535
77. Gray NS Wodicka L Thunnissen AM Norman TC Kwon S Espinoza FH Morgan DO Barnes G LeClerc S Meijer L Kim SH Lockhart DJ Schultz PG Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors Science 1998, 281:533-538. 10.1126/science.281.5376.533 9677190
78. Matsuoka M Jeang KT Human T-cell leukemia virus type I at age 25: A progress report Cancer Res 2005, 65:4467-4470. 10.1158/ 0008-5472.CAN-05-0559 15930259
79. Sun SC Yamaoka S Activation of NF-kappaB by HTLV-I and implications for cell transformation Oncogene 2005, 24:5952-5964. 10.1038/sj.onc.1208969 16155602
80. Kudoh A Daikoku T Sugaya Y Isomura H Fujita M Kiyono T Nishiyama Y Tsurumi T Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication J Virol 2004, 78:104-115. 303396 14671092 10.1128/JVI.78.1.104-115.2004
81. Wang L Deng L Wu K de la Fuente C Wang D Kehn K Maddukuri A Baylor S Santiago F Agbottah E Trigon S Morange M Mahieux R Kashanchi F Inhibition of HTLV-1 transcription by cyclin dependent kinase inhibitors Mol Cell Biochem 2002, 237:137-153. 10.1023/A:1016555821581 12236581
82. Gill PS Harrington W Jr. Kaplan MH Ribeiro RC Bennett JM Liebman HA Bernstein-Singer M Espina BM Cabral L Allen S Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine N Engl J Med 1995, 332:1744-1748. 10.1056/NEJM199506293322603 7760890
83. Hermine O Bouscary D Gessain A Turlure P Leblond V Franck N Buzyn-Veil A Rio B Macintyre E Dreyfus F Brief report: Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa N Engl J Med 1995, 332:1749-1751. 10.1056/NEJM199506293322604 7760891
84. Bazarbachi A Hermine O Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients J Acquir Immune Defic Syndr Hum Retrovirol 1996, 13(Suppl 1):S186-90. 10.1097/00042560-199600001-00028 87977
85. Hermine O Allard I Levy V Arnulf B Gessain A Bazarbachi A A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma Hematol J 2002, 3:276-282. 10.1038/sj.thj.6200195 12522449
86. Hermine O Dombret H Poupon J Arnulf B Lefrere F Rousselot P Damaj G Delarue R Fermand JP Brouet JC Degos L Varet B de The H Bazarbachi A Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma Hematol J 2004, 5:130-134. 10.1038/sj.thj.6200374 15048063
87. Kfoury Y Nasr R Hermine O de The H Bazarbachi A Proapoptotic regimes for HTLV-I-transformed cells: Targeting Tax and the NF-kappaB pathway Cell Death Differ 2005, 12(Suppl 1):871-877. 10.1038/sj.cdd.4401624 15846376